Inhibikase Therapeutics (IKT) announced that it expects to advance IKT-001 to a global pivotal Phase 3 clinical study in Pulmonary Arterial Hypertension. The Phase 3 study, named IMPROVE-PAH, is expected to be initiated in the first quarter of 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IKT: